US5948634A
(en)
*
|
1988-12-21 |
1999-09-07 |
The General Hospital Coporation |
Neural thread protein gene expression and detection of alzheimer's disease
|
US5955589A
(en)
*
|
1991-12-24 |
1999-09-21 |
Isis Pharmaceuticals Inc. |
Gapped 2' modified oligonucleotides
|
US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US5670633A
(en)
*
|
1990-01-11 |
1997-09-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
US5872232A
(en)
*
|
1990-01-11 |
1999-02-16 |
Isis Pharmaceuticals Inc. |
2'-O-modified oligonucleotides
|
US5859221A
(en)
*
|
1990-01-11 |
1999-01-12 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US5623065A
(en)
*
|
1990-08-13 |
1997-04-22 |
Isis Pharmaceuticals, Inc. |
Gapped 2' modified oligonucleotides
|
US6005087A
(en)
|
1995-06-06 |
1999-12-21 |
Isis Pharmaceuticals, Inc. |
2'-modified oligonucleotides
|
US6395888B1
(en)
*
|
1996-02-01 |
2002-05-28 |
Gilead Sciences, Inc. |
High affinity nucleic acid ligands of complement system proteins
|
AU650032B2
(en)
*
|
1990-06-19 |
1994-06-09 |
Gene Shears Pty. Limited |
Endonucleases
|
PL169576B1
(pl)
*
|
1990-10-12 |
1996-08-30 |
Max Planck Gesellschaft |
Sposób wytwarzania czasteczki RNA o aktywnosci katalitycznej PL PL
|
US7015315B1
(en)
|
1991-12-24 |
2006-03-21 |
Isis Pharmaceuticals, Inc. |
Gapped oligonucleotides
|
US5965722A
(en)
*
|
1991-05-21 |
1999-10-12 |
Isis Pharmaceuticals, Inc. |
Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
|
US6307040B1
(en)
|
1992-03-05 |
2001-10-23 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides that detect and modulate gene expression
|
US7119184B2
(en)
|
1991-08-12 |
2006-10-10 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides having A-DNA form and B-DNA form conformational geometry
|
US5856455A
(en)
*
|
1991-12-24 |
1999-01-05 |
Isis Pharmaceuticals, Inc. |
Gapped 2'-modified oligonucleotides
|
US6277603B1
(en)
|
1991-12-24 |
2001-08-21 |
Isis Pharmaceuticals, Inc. |
PNA-DNA-PNA chimeric macromolecules
|
EP0618925B2
(de)
*
|
1991-12-24 |
2012-04-18 |
Isis Pharmaceuticals, Inc. |
Antisense oligonukleotide
|
US5652094A
(en)
*
|
1992-01-31 |
1997-07-29 |
University Of Montreal |
Nucleozymes
|
US6204027B1
(en)
*
|
1992-02-26 |
2001-03-20 |
University Of Massachusetts Worcester |
Ribozymes having 2′-O substituted nucleotides in the flanking sequences
|
US6469158B1
(en)
*
|
1992-05-14 |
2002-10-22 |
Ribozyme Pharmaceuticals, Incorporated |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US5804683A
(en)
*
|
1992-05-14 |
1998-09-08 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA with alkylamine
|
US20040127446A1
(en)
*
|
1992-05-14 |
2004-07-01 |
Lawrence Blatt |
Oligonucleotide mediated inhibition of hepatitis B virus and hepatitis C virus replication
|
US5977343A
(en)
|
1992-05-14 |
1999-11-02 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
US20030206887A1
(en)
*
|
1992-05-14 |
2003-11-06 |
David Morrissey |
RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA)
|
US20040054156A1
(en)
*
|
1992-05-14 |
2004-03-18 |
Kenneth Draper |
Method and reagent for inhibiting hepatitis B viral replication
|
US20030125270A1
(en)
*
|
2000-12-18 |
2003-07-03 |
Lawrence Blatt |
Enzymatic nucleic acid treatment of diseases or conditions related to hepatitis C virus infection
|
US5686599A
(en)
*
|
1992-05-14 |
1997-11-11 |
Ribozyme Pharmaceuticals, Inc. |
Synthesis, deprotection, analysis and purification of RNA and ribozymes
|
TW244371B
(de)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
US5652355A
(en)
*
|
1992-07-23 |
1997-07-29 |
Worcester Foundation For Experimental Biology |
Hybrid oligonucleotide phosphorothioates
|
US5646042A
(en)
*
|
1992-08-26 |
1997-07-08 |
Ribozyme Pharmaceuticals, Inc. |
C-myb targeted ribozymes
|
US5891684A
(en)
*
|
1992-10-15 |
1999-04-06 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
IL107480A0
(en)
*
|
1992-11-03 |
1994-02-27 |
Gene Shears Pty Ltd |
Tnf-x ribozymes and degradation resistant mrna derivatives linked to tnf-x ribozymes
|
US5864028A
(en)
*
|
1992-11-03 |
1999-01-26 |
Gene Shears Pty. Limited |
Degradation resistant mRNA derivatives linked to TNF-α ribozymes
|
GB9225427D0
(en)
*
|
1992-12-04 |
1993-01-27 |
Ribonetics Gmbh |
Oligonucleotides with rna cleavage activity
|
US5612215A
(en)
*
|
1992-12-07 |
1997-03-18 |
Ribozyme Pharmaceuticals, Inc. |
Stromelysin targeted ribozymes
|
US5616488A
(en)
*
|
1992-12-07 |
1997-04-01 |
Ribozyme Pharmaceuticals, Inc. |
IL-5 targeted ribozymes
|
US5837542A
(en)
*
|
1992-12-07 |
1998-11-17 |
Ribozyme Pharmaceuticals, Inc. |
Intercellular adhesion molecule-1 (ICAM-1) ribozymes
|
US5658780A
(en)
|
1992-12-07 |
1997-08-19 |
Ribozyme Pharmaceuticals, Inc. |
Rel a targeted ribozymes
|
US5811300A
(en)
*
|
1992-12-07 |
1998-09-22 |
Ribozyme Pharmaceuticals, Inc. |
TNF-α ribozymes
|
US5817635A
(en)
*
|
1993-08-09 |
1998-10-06 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Modified ribozymes
|
EP1253199A1
(de)
|
1993-09-02 |
2002-10-30 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatische Nukleinsaüre die abasische Gruppen enthalten
|
AU7623194A
(en)
*
|
1993-09-03 |
1995-03-22 |
Vpi Holdings Ltd. |
Oligonucleotides with rna cleavage activity
|
US5861288A
(en)
*
|
1993-10-18 |
1999-01-19 |
Ribozyme Pharmaceuticals, Inc. |
Catalytic DNA
|
EP0725788B1
(de)
*
|
1993-10-27 |
1998-12-16 |
Ribozyme Pharmaceuticals, Inc. |
2'-amido-und 2'-peptido-modifizierte oligonukleotide
|
AU687479B2
(en)
|
1993-11-08 |
1998-02-26 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
AU730347B2
(en)
*
|
1993-11-08 |
2001-03-08 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
US6897016B1
(en)
|
1993-11-12 |
2005-05-24 |
The Regents Of The University Of Colorado |
Alteration of sequence of a target molecule
|
CA2183992A1
(en)
*
|
1994-02-23 |
1995-08-31 |
Dan T. Stinchcomb |
Method and reagent for inhibiting the expression of disease related genes
|
EP1260586A3
(de)
*
|
1994-02-23 |
2004-04-28 |
Ribozyme Pharmaceuticals, Inc. |
Verfahren und Verbindung zur Verringerung des Expression von Genen, die in Verbindung mit Krankheiten stehen
|
US5902880A
(en)
*
|
1994-08-19 |
1999-05-11 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US5693532A
(en)
*
|
1994-11-04 |
1997-12-02 |
Ribozyme Pharmaceuticals, Inc. |
Respiratory syncytial virus ribozymes
|
US5639647A
(en)
*
|
1994-03-29 |
1997-06-17 |
Ribozyme Pharmaceuticals, Inc. |
2'-deoxy-2'alkylnucleotide containing nucleic acid
|
US5631359A
(en)
*
|
1994-10-11 |
1997-05-20 |
Ribozyme Pharmaceuticals, Inc. |
Hairpin ribozymes
|
US5627053A
(en)
*
|
1994-03-29 |
1997-05-06 |
Ribozyme Pharmaceuticals, Inc. |
2'deoxy-2'-alkylnucleotide containing nucleic acid
|
US6103890A
(en)
*
|
1994-05-18 |
2000-08-15 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids that cleave C-fos
|
US5633133A
(en)
*
|
1994-07-14 |
1997-05-27 |
Long; David M. |
Ligation with hammerhead ribozymes
|
US6146886A
(en)
*
|
1994-08-19 |
2000-11-14 |
Ribozyme Pharmaceuticals, Inc. |
RNA polymerase III-based expression of therapeutic RNAs
|
US5599706A
(en)
*
|
1994-09-23 |
1997-02-04 |
Stinchcomb; Dan T. |
Ribozymes targeted to apo(a) mRNA
|
US5700923A
(en)
*
|
1994-09-29 |
1997-12-23 |
Hybridon, Inc. |
Finderons and methods of their preparation and use
|
US5672501A
(en)
*
|
1994-12-23 |
1997-09-30 |
Ribozyme Pharmaceuticals, Inc. |
Base-modified enzymatic nucleic acid
|
US5716824A
(en)
|
1995-04-20 |
1998-02-10 |
Ribozyme Pharmaceuticals, Inc. |
2'-O-alkylthioalkyl and 2-C-alkylthioalkyl-containing enzymatic nucleic acids (ribozymes)
|
US5545729A
(en)
*
|
1994-12-22 |
1996-08-13 |
Hybridon, Inc. |
Stabilized ribozyme analogs
|
US5705388A
(en)
*
|
1994-12-23 |
1998-01-06 |
Ribozyme Pharmaceuticals, Inc. |
CETP Ribozymes
|
US5804560A
(en)
*
|
1995-01-06 |
1998-09-08 |
Sibia Neurosciences, Inc. |
Peptide and peptide analog protease inhibitors
|
US6017887A
(en)
*
|
1995-01-06 |
2000-01-25 |
Sibia Neurosciences, Inc. |
Peptide, peptide analog and amino acid analog protease inhibitors
|
US5663064A
(en)
*
|
1995-01-13 |
1997-09-02 |
University Of Vermont |
Ribozymes with RNA protein binding site
|
US5877021A
(en)
|
1995-07-07 |
1999-03-02 |
Ribozyme Pharmaceuticals, Inc. |
B7-1 targeted ribozymes
|
US6346398B1
(en)
|
1995-10-26 |
2002-02-12 |
Ribozyme Pharmaceuticals, Inc. |
Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
|
US7034009B2
(en)
*
|
1995-10-26 |
2006-04-25 |
Sirna Therapeutics, Inc. |
Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
|
US20040142895A1
(en)
*
|
1995-10-26 |
2004-07-22 |
Sirna Therapeutics, Inc. |
Nucleic acid-based modulation of gene expression in the vascular endothelial growth factor pathway
|
US20040220128A1
(en)
*
|
1995-10-26 |
2004-11-04 |
Sirna Therapeutics, Inc. |
Nucleic acid based modulation of female reproductive diseases and conditions
|
US20040102389A1
(en)
*
|
1995-10-26 |
2004-05-27 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid-mediated treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)
|
CA2237528A1
(en)
*
|
1995-11-14 |
1997-05-22 |
Vimrx Holdings, Ltd. |
Chimeric oligomers having an rna-cleavage activity
|
US5998203A
(en)
*
|
1996-04-16 |
1999-12-07 |
Ribozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acids containing 5'-and/or 3'-cap structures
|
DK0808898T3
(da)
*
|
1996-05-24 |
2004-09-27 |
Aventis Pharma Gmbh |
Reagens og fremgangsmåde til inhibering af N-ras-ekspression
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US20030044941A1
(en)
|
1996-06-06 |
2003-03-06 |
Crooke Stanley T. |
Human RNase III and compositions and uses thereof
|
US7812149B2
(en)
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US5807743A
(en)
*
|
1996-12-03 |
1998-09-15 |
Ribozyme Pharmaceuticals, Inc. |
Interleukin-2 receptor gamma-chain ribozymes
|
DE69738768D1
(de)
*
|
1996-12-13 |
2008-07-24 |
Novartis Vaccines & Diagnostic |
Analyse und separation von pdgf-proteinen
|
JP2002514913A
(ja)
*
|
1996-12-19 |
2002-05-21 |
エール ユニバーシティ |
生反応性アロステリックポリヌクレオチド
|
US6248878B1
(en)
|
1996-12-24 |
2001-06-19 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside analogs
|
US20030186909A1
(en)
*
|
1997-01-27 |
2003-10-02 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
|
US6057156A
(en)
|
1997-01-31 |
2000-05-02 |
Robozyme Pharmaceuticals, Inc. |
Enzymatic nucleic acid treatment of diseases or conditions related to levels of epidermal growth factor receptors
|
US6159951A
(en)
*
|
1997-02-13 |
2000-12-12 |
Ribozyme Pharmaceuticals Inc. |
2'-O-amino-containing nucleoside analogs and polynucleotides
|
KR20000075748A
(ko)
|
1997-02-26 |
2000-12-26 |
마빈 씨. 구트리 |
알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
|
US7226730B1
(en)
|
1997-02-26 |
2007-06-05 |
The General Hospital Corporation |
Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
|
US6251666B1
(en)
|
1997-03-31 |
2001-06-26 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid catalysts comprising L-nucleotide analogs
|
US6280936B1
(en)
|
1997-06-09 |
2001-08-28 |
Ribozyme Pharmaceuticals, Inc. |
Method for screening nucleic acid catalysts
|
US6548657B1
(en)
|
1997-06-09 |
2003-04-15 |
Ribozyme Pharmaceuticals, Inc. |
Method for screening nucleic acid catalysts
|
US6183959B1
(en)
|
1997-07-03 |
2001-02-06 |
Ribozyme Pharmaceuticals, Inc. |
Method for target site selection and discovery
|
US6316612B1
(en)
|
1997-08-22 |
2001-11-13 |
Ribozyme Pharmaceuticals, Inc. |
Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides
|
US6656731B1
(en)
|
1997-09-22 |
2003-12-02 |
Max Planck Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Nucleic acid catalysts with endonuclease activity
|
AU750947C
(en)
*
|
1997-09-22 |
2003-05-22 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. |
Nucleic acid catalysts with endonuclease activity
|
US6054576A
(en)
|
1997-10-02 |
2000-04-25 |
Ribozyme Pharmaceuticals, Inc. |
Deprotection of RNA
|
US6127535A
(en)
*
|
1997-11-05 |
2000-10-03 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
US6482932B1
(en)
*
|
1997-11-05 |
2002-11-19 |
Ribozyme Pharmaceuticals, Incorporated |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
AU3751299A
(en)
|
1998-04-20 |
1999-11-08 |
Ribozyme Pharmaceuticals, Inc. |
Nucleic acid molecules with novel chemical compositions capable of modulating gene expression
|
CA2230203A1
(en)
|
1998-04-29 |
1999-10-29 |
Universite De Sherbrooke |
Delta ribozyme for rna cleavage
|
AU6021799A
(en)
*
|
1998-08-26 |
2000-04-03 |
South Alabama Medical Science Foundation |
T-type calcium channel
|
US20030125269A1
(en)
*
|
1998-08-26 |
2003-07-03 |
Ming Li |
T-type calcium channel
|
US6175004B1
(en)
*
|
1998-09-01 |
2001-01-16 |
Isis Pharmaceuticals, Inc. |
Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
|
US6995259B1
(en)
|
1998-10-23 |
2006-02-07 |
Sirna Therapeutics, Inc. |
Method for the chemical synthesis of oligonucleotides
|
IL126732A0
(en)
*
|
1998-10-23 |
1999-08-17 |
Intelligene Ltd |
Pro drug
|
EP1180114B1
(de)
|
1999-04-27 |
2011-09-21 |
The Trustees of The University of Pennsylvania |
Verwendung von Resistin spezifischen Antikörpern in der Behandlung von Diabetes
|
EP1183389A2
(de)
|
1999-04-30 |
2002-03-06 |
University of Florida |
Ribozym zusamensetzungen verabreicht durch adeno asozierte viren und dessen verwendungen
|
US6617442B1
(en)
*
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
US6831171B2
(en)
|
2000-02-08 |
2004-12-14 |
Yale University |
Nucleic acid catalysts with endonuclease activity
|
US8273866B2
(en)
*
|
2002-02-20 |
2012-09-25 |
Merck Sharp & Dohme Corp. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
|
US8202979B2
(en)
*
|
2002-02-20 |
2012-06-19 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
|
US7491805B2
(en)
*
|
2001-05-18 |
2009-02-17 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050233329A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
Inhibition of gene expression using duplex forming oligonucleotides
|
WO2003070918A2
(en)
|
2002-02-20 |
2003-08-28 |
Ribozyme Pharmaceuticals, Incorporated |
Rna interference by modified short interfering nucleic acid
|
US20080039414A1
(en)
*
|
2002-02-20 |
2008-02-14 |
Sima Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20050032733A1
(en)
*
|
2001-05-18 |
2005-02-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
|
AU3811101A
(en)
*
|
2000-02-11 |
2001-08-20 |
Lawrence Blatt |
Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression
|
US20070026394A1
(en)
*
|
2000-02-11 |
2007-02-01 |
Lawrence Blatt |
Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies
|
US7833992B2
(en)
*
|
2001-05-18 |
2010-11-16 |
Merck Sharpe & Dohme |
Conjugates and compositions for cellular delivery
|
US6846486B1
(en)
|
2000-02-24 |
2005-01-25 |
Advanced Biotherapy Concepts, Inc. |
Method of treating allergy by administering an anti-histamine antibody
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20040009510A1
(en)
*
|
2000-03-06 |
2004-01-15 |
Scott Seiwert |
Allosteric nucleic acid sensor molecules
|
US20030065155A1
(en)
*
|
2000-03-06 |
2003-04-03 |
Nassim Usman |
Nucleic acid sensor molecules
|
CA2404890C
(en)
|
2000-03-30 |
2013-11-19 |
Whitehead Institute For Biomedical Research |
Rna sequence-specific mediators of rna interference
|
ATE396265T1
(de)
|
2000-06-28 |
2008-06-15 |
Corixa Corp |
Zusammensetzungen und verfahren für therapie und diagnose von lungenkrebs
|
US20030190635A1
(en)
*
|
2002-02-20 |
2003-10-09 |
Mcswiggen James A. |
RNA interference mediated treatment of Alzheimer's disease using short interfering RNA
|
US20050209179A1
(en)
*
|
2000-08-30 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
US20080032942A1
(en)
*
|
2000-08-30 |
2008-02-07 |
Mcswiggen James |
RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
|
BRPI0115814B8
(pt)
|
2000-12-01 |
2021-05-25 |
Europaeisches Laboratorium Fuer Molekularbiologie Embl |
moléculas de rna de filamento duplo, seu método de preparação e composição farmacêutica compreendendo as mesmas
|
US7049059B2
(en)
*
|
2000-12-01 |
2006-05-23 |
Response Genetics, Inc. |
Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
|
ES2328796T3
(es)
|
2001-03-14 |
2009-11-18 |
Myriad Genetics, Inc. |
Interaccion tsg101-gag y uso de la misma.
|
JP2004532022A
(ja)
*
|
2001-03-26 |
2004-10-21 |
サーナ・セラピューティクス・インコーポレイテッド |
B型肝炎ウイルスおよびc型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
|
AU2002305123B2
(en)
|
2001-03-30 |
2006-10-05 |
Philadelphia Health And Education Corporation |
Immunomodulation and effect on cell processes relating to serotonin family receptors
|
WO2002089747A2
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
US20080161256A1
(en)
*
|
2001-05-18 |
2008-07-03 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20060019913A1
(en)
*
|
2001-05-18 |
2006-01-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
|
US20050054596A1
(en)
*
|
2001-11-30 |
2005-03-10 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050282188A1
(en)
*
|
2001-05-18 |
2005-12-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20040019001A1
(en)
*
|
2002-02-20 |
2004-01-29 |
Mcswiggen James A. |
RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA
|
US20040198682A1
(en)
*
|
2001-11-30 |
2004-10-07 |
Mcswiggen James |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
|
US7517864B2
(en)
*
|
2001-05-18 |
2009-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050124567A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
|
US20050182007A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
US20060241075A1
(en)
*
|
2001-05-18 |
2006-10-26 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
|
US20050222066A1
(en)
*
|
2001-05-18 |
2005-10-06 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050203040A1
(en)
*
|
2001-05-18 |
2005-09-15 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
|
US20050176666A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
|
US20050079610A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
|
US20050159379A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
|
US20050124566A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
|
US20050233344A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
|
US20050080031A1
(en)
*
|
2001-05-18 |
2005-04-14 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
|
US20050119211A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
|
WO2002097114A2
(en)
*
|
2001-05-29 |
2002-12-05 |
Sirna Therapeutics, Inc. |
Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
|
US20030170891A1
(en)
*
|
2001-06-06 |
2003-09-11 |
Mcswiggen James A. |
RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050287128A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
|
US20050130181A1
(en)
*
|
2001-05-18 |
2005-06-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
|
US20050164224A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
|
US20070270579A1
(en)
*
|
2001-05-18 |
2007-11-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20060142225A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
|
US20070042983A1
(en)
*
|
2001-05-18 |
2007-02-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
|
US20050233997A1
(en)
*
|
2001-05-18 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
|
US20050137155A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
|
US20050288242A1
(en)
*
|
2001-05-18 |
2005-12-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
|
US20050176664A1
(en)
*
|
2001-05-18 |
2005-08-11 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
|
US20050159382A1
(en)
*
|
2001-05-18 |
2005-07-21 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
|
US20050153915A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
|
US20050209180A1
(en)
*
|
2001-05-18 |
2005-09-22 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
|
US20050191638A1
(en)
*
|
2002-02-20 |
2005-09-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US20050196765A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
|
US20050182009A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
|
US20050187174A1
(en)
*
|
2001-05-18 |
2005-08-25 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
|
US20050196767A1
(en)
*
|
2001-05-18 |
2005-09-08 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
|
US20050164967A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
|
US20050256068A1
(en)
*
|
2001-05-18 |
2005-11-17 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
|
US20060211642A1
(en)
*
|
2001-05-18 |
2006-09-21 |
Sirna Therapeutics, Inc. |
RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
|
US20040209831A1
(en)
*
|
2002-02-20 |
2004-10-21 |
Mcswiggen James |
RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
|
US20050148530A1
(en)
|
2002-02-20 |
2005-07-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20030175950A1
(en)
*
|
2001-05-29 |
2003-09-18 |
Mcswiggen James A. |
RNA interference mediated inhibition of HIV gene expression using short interfering RNA
|
US20050164968A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
|
US20060142226A1
(en)
*
|
2001-05-18 |
2006-06-29 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
|
US20050136436A1
(en)
*
|
2001-05-18 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
|
US7109165B2
(en)
|
2001-05-18 |
2006-09-19 |
Sirna Therapeutics, Inc. |
Conjugates and compositions for cellular delivery
|
US20050164966A1
(en)
*
|
2001-05-18 |
2005-07-28 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20080188430A1
(en)
*
|
2001-05-18 |
2008-08-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
|
US20050124568A1
(en)
*
|
2001-05-18 |
2005-06-09 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
|
US20050227935A1
(en)
*
|
2001-05-18 |
2005-10-13 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
|
US20050119212A1
(en)
*
|
2001-05-18 |
2005-06-02 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
|
US20040006035A1
(en)
*
|
2001-05-29 |
2004-01-08 |
Dennis Macejak |
Nucleic acid mediated disruption of HIV fusogenic peptide interactions
|
US20050054598A1
(en)
*
|
2002-02-20 |
2005-03-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050233996A1
(en)
*
|
2002-02-20 |
2005-10-20 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
|
US20050014172A1
(en)
*
|
2002-02-20 |
2005-01-20 |
Ivan Richards |
RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
|
US9994853B2
(en)
|
2001-05-18 |
2018-06-12 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US20050153914A1
(en)
*
|
2001-05-18 |
2005-07-14 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
|
US20050267058A1
(en)
*
|
2001-05-18 |
2005-12-01 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
|
US20050182006A1
(en)
*
|
2001-05-18 |
2005-08-18 |
Sirna Therapeutics, Inc |
RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
|
US20050143333A1
(en)
*
|
2001-05-18 |
2005-06-30 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
|
EP3231445A1
(de)
|
2001-05-18 |
2017-10-18 |
Sirna Therapeutics, Inc. |
Konjugate und zusammensetzungen zur zellulären verabreichung
|
US20050159376A1
(en)
*
|
2002-02-20 |
2005-07-21 |
Slrna Therapeutics, Inc. |
RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
|
US20030140362A1
(en)
*
|
2001-06-08 |
2003-07-24 |
Dennis Macejak |
In vivo models for screening inhibitors of hepatitis B virus
|
US7205399B1
(en)
|
2001-07-06 |
2007-04-17 |
Sirna Therapeutics, Inc. |
Methods and reagents for oligonucleotide synthesis
|
WO2003008628A2
(en)
*
|
2001-07-20 |
2003-01-30 |
Ribozyme Pharmacuticals, Inc. |
Enzymatic nucleic acid peptide conjugates
|
AU2002365084A1
(en)
*
|
2001-10-19 |
2003-07-24 |
Sirna Therapeutics, Inc |
Method and reagent for the detection of proteins and peptides
|
US20040138163A1
(en)
*
|
2002-05-29 |
2004-07-15 |
Mcswiggen James |
RNA interference mediated inhibition of vascular edothelial growth factor and vascular edothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20070203333A1
(en)
*
|
2001-11-30 |
2007-08-30 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20050075304A1
(en)
*
|
2001-11-30 |
2005-04-07 |
Mcswiggen James |
RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
|
US20030219775A1
(en)
*
|
2001-12-14 |
2003-11-27 |
Ward David C. |
Nucleic acid diagnostic reagents and methods for detecting nucleic acids, polynucleotides and oligonucleotides
|
ES2405790T3
(es)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Composiciones y métodos para la terapia y el diagnóstico de enfermedad inflamatoria del intestino
|
US20050042632A1
(en)
*
|
2002-02-13 |
2005-02-24 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for nucleic acids
|
US7071311B2
(en)
*
|
2002-02-13 |
2006-07-04 |
Sirna Therapeutics, Inc. |
Antibodies having specificity for 2′-C-allyl nucleic acids
|
US20050137153A1
(en)
*
|
2002-02-20 |
2005-06-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
|
WO2003106476A1
(en)
*
|
2002-02-20 |
2003-12-24 |
Sirna Therapeutics, Inc |
Nucleic acid mediated inhibition of enterococcus infection and cytolysin toxin activity
|
US20050222064A1
(en)
*
|
2002-02-20 |
2005-10-06 |
Sirna Therapeutics, Inc. |
Polycationic compositions for cellular delivery of polynucleotides
|
US9657294B2
(en)
|
2002-02-20 |
2017-05-23 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
AU2003207708A1
(en)
|
2002-02-20 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Rna interference mediated inhibition of map kinase genes
|
US20050096284A1
(en)
*
|
2002-02-20 |
2005-05-05 |
Sirna Therapeutics, Inc. |
RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
|
US9181551B2
(en)
|
2002-02-20 |
2015-11-10 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20030195164A1
(en)
*
|
2002-04-16 |
2003-10-16 |
Veli-Matti Kahari |
Novel ribozyme and its use
|
US20040018520A1
(en)
*
|
2002-04-22 |
2004-01-29 |
James Thompson |
Trans-splicing enzymatic nucleic acid mediated biopharmaceutical and protein
|
US20030224435A1
(en)
*
|
2002-05-16 |
2003-12-04 |
Scott Seiwert |
Detection of abused substances and their metabolites using nucleic acid sensor molecules
|
US7767803B2
(en)
|
2002-06-18 |
2010-08-03 |
Archemix Corp. |
Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
|
US6989442B2
(en)
*
|
2002-07-12 |
2006-01-24 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
US7655790B2
(en)
|
2002-07-12 |
2010-02-02 |
Sirna Therapeutics, Inc. |
Deprotection and purification of oligonucleotides and their derivatives
|
CA2492463A1
(en)
*
|
2002-07-25 |
2004-02-05 |
Archemix Corporation |
Regulated aptamer therapeutics
|
SI3222724T1
(sl)
|
2002-08-05 |
2019-03-29 |
Silence Therapeutics Gmbh |
Nadaljnje nove oblike molekul interferenčne RNA
|
US7956176B2
(en)
|
2002-09-05 |
2011-06-07 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
|
US20080260744A1
(en)
|
2002-09-09 |
2008-10-23 |
Omeros Corporation |
G protein coupled receptors and uses thereof
|
US9303262B2
(en)
|
2002-09-17 |
2016-04-05 |
Archemix Llc |
Methods for identifying aptamer regulators
|
US20040137471A1
(en)
*
|
2002-09-18 |
2004-07-15 |
Timothy Vickers |
Efficient reduction of target RNA's by single-and double-stranded oligomeric compounds
|
WO2004029212A2
(en)
|
2002-09-25 |
2004-04-08 |
University Of Massachusetts |
In vivo gene silencing by chemically modified and stable sirna
|
US8604183B2
(en)
|
2002-11-05 |
2013-12-10 |
Isis Pharmaceuticals, Inc. |
Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
|
US20050124565A1
(en)
*
|
2002-11-21 |
2005-06-09 |
Diener John L. |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US10100316B2
(en)
*
|
2002-11-21 |
2018-10-16 |
Archemix Llc |
Aptamers comprising CPG motifs
|
US8853376B2
(en)
|
2002-11-21 |
2014-10-07 |
Archemix Llc |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US8039443B2
(en)
|
2002-11-21 |
2011-10-18 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US20040180360A1
(en)
*
|
2002-11-21 |
2004-09-16 |
Charles Wilson |
Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same
|
WO2004050899A2
(en)
*
|
2002-12-03 |
2004-06-17 |
Archemix Corporation |
Method for in vitro selection of 2’-substituted nucleic acids
|
US20050037394A1
(en)
*
|
2002-12-03 |
2005-02-17 |
Keefe Anthony D. |
Method for in vitro selection of 2'-substituted nucleic acids
|
US20040209353A1
(en)
*
|
2002-12-12 |
2004-10-21 |
Chiron Corporation |
Biological sample storage device and method for biological sample contamination testing
|
US20040231231A1
(en)
*
|
2002-12-20 |
2004-11-25 |
Cataldo Dominic A. |
Use of colloidal clays for sustained release of active ingredients
|
US20030232400A1
(en)
*
|
2002-12-20 |
2003-12-18 |
Susan Radka |
Methods of screening subjects for expression of soluble receptors of vascular endothelial growth factor (VEGF) for use in managing treatment and determining prognostic outcome
|
WO2004060323A2
(en)
*
|
2003-01-02 |
2004-07-22 |
The Research Foundation Of State University Of Newyork |
Novel inhibitors of poxvirus replication
|
EP1613269B1
(de)
|
2003-04-04 |
2015-02-25 |
Incyte Corporation |
Zusammensetzungen, verfahren und kits in zusammenhang mit her-2 spaltung
|
AU2004231740A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Ofnew York |
Desmoglein 4 is a novel gene involved in hair growth
|
CA2523260A1
(en)
|
2003-04-21 |
2004-11-04 |
Archemix Corporation |
Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
|
US20050250106A1
(en)
*
|
2003-04-24 |
2005-11-10 |
David Epstein |
Gene knock-down by intracellular expression of aptamers
|
EP3222294A1
(de)
|
2003-04-30 |
2017-09-27 |
Sirna Therapeutics, Inc. |
Konjugate und zusammensetzungen zur zellulären verabreichung
|
US20060019914A1
(en)
*
|
2004-02-11 |
2006-01-26 |
University Of Tennessee Research Foundation |
Inhibition of tumor growth and invasion by anti-matrix metalloproteinase DNAzymes
|
EP1727567B1
(de)
|
2004-02-12 |
2013-07-03 |
Archemix LLC |
Zur Behandlung von Erkrankungen in Verbindung mit dem Komplementsystem geeignete Aptamer-Therapeutika
|
US7803931B2
(en)
|
2004-02-12 |
2010-09-28 |
Archemix Corp. |
Aptamer therapeutics useful in the treatment of complement-related disorders
|
US20060193821A1
(en)
*
|
2004-03-05 |
2006-08-31 |
Diener John L |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
AU2005220910A1
(en)
*
|
2004-03-05 |
2005-09-22 |
Archemix Corp. |
Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
|
US8569474B2
(en)
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
EP1735009A4
(de)
|
2004-03-12 |
2011-03-30 |
Alnylam Pharmaceuticals Inc |
Irna mittel targeting vegf
|
US20080214489A1
(en)
*
|
2004-04-19 |
2008-09-04 |
Anthony Dominic Keefe |
Aptamer-mediated intracellular delivery of oligonucleotides
|
CA2557532A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Angela M. Christiano |
Inhibition of hairless protein mrna
|
US7579450B2
(en)
|
2004-04-26 |
2009-08-25 |
Archemix Corp. |
Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics
|
US20060040882A1
(en)
|
2004-05-04 |
2006-02-23 |
Lishan Chen |
Compostions and methods for enhancing delivery of nucleic acids into cells and for modifying expression of target genes in cells
|
US10508277B2
(en)
|
2004-05-24 |
2019-12-17 |
Sirna Therapeutics, Inc. |
Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
|
US8394947B2
(en)
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
WO2006112869A2
(en)
|
2004-07-19 |
2006-10-26 |
Baylor College Of Medicine |
Modulation of cytokine signaling regulators and applications for immunotherapy
|
AU2005272920B2
(en)
|
2004-08-10 |
2011-05-12 |
Institute For Multiple Myeloma And Bone Cancer Research |
Methods of regulating differentiation and treating of multiple myeloma
|
EP1789096A4
(de)
|
2004-09-07 |
2009-07-08 |
Archemix Corp |
Aptamere für den von-willebrand-faktor und ihre verwendung als therapeutika für thrombotische erkrankungen
|
KR20070101226A
(ko)
|
2004-09-07 |
2007-10-16 |
아케믹스 코포레이션 |
앱타머의 약화학
|
US7566701B2
(en)
|
2004-09-07 |
2009-07-28 |
Archemix Corp. |
Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics
|
US7884086B2
(en)
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
EP2436391A3
(de)
|
2004-11-02 |
2012-07-04 |
Archemix LLC |
Stabilisierte Aptamere für einen aus Plättchen gewonnenen Wachstumsfaktor und ihre Verwendung als Krebstherapiemittel
|
ES2401285T3
(es)
|
2004-12-16 |
2013-04-18 |
The Regents Of The University Of California |
Fármacos con el pulmón como diana
|
CA2600418A1
(en)
*
|
2005-03-07 |
2006-09-14 |
Archemix Corp. |
Stabilized aptamers to psma and their use as prostate cancer therapeutics
|
EP1866414B9
(de)
|
2005-03-31 |
2012-10-03 |
Calando Pharmaceuticals, Inc. |
Inhibitoren der untereinheit 2 der ribonukleotidreduktase und ihre verwendungen
|
US20090075342A1
(en)
*
|
2005-04-26 |
2009-03-19 |
Sharon Cload |
Metabolic profile directed aptamer medicinal chemistry
|
US7868159B2
(en)
|
2005-06-23 |
2011-01-11 |
Baylor College Of Medicine |
Modulation of negative immune regulators and applications for immunotherapy
|
ATE522626T1
(de)
|
2005-06-28 |
2011-09-15 |
Medtronic Inc |
Verfahren und nukleotid-sequenzen, die bevorzugt die expression eines mutierten huntingtin-genes unterdrücken
|
US8101385B2
(en)
|
2005-06-30 |
2012-01-24 |
Archemix Corp. |
Materials and methods for the generation of transcripts comprising modified nucleotides
|
KR20080025181A
(ko)
|
2005-06-30 |
2008-03-19 |
아케믹스 코포레이션 |
완전 2'-변형된 핵산 전사체를 생성하기 위한 물질 및 방법
|
US20090176725A1
(en)
*
|
2005-08-17 |
2009-07-09 |
Sirna Therapeutics Inc. |
Chemically modified short interfering nucleic acid molecules that mediate rna interference
|
FI20055712A0
(fi)
*
|
2005-12-29 |
2005-12-29 |
Wallac Oy |
Makrosykliset oligonukleotiidien leimausreagenssit ja niistä johdetut konjugaatit
|
EP1981902B1
(de)
|
2006-01-27 |
2015-07-29 |
Biogen MA Inc. |
Nogo-rezeptorantagonisten
|
US7922000B2
(en)
*
|
2006-02-15 |
2011-04-12 |
Miraial Co., Ltd. |
Thin plate container with a stack of removable loading trays
|
RU2477137C2
(ru)
|
2006-03-08 |
2013-03-10 |
АРКЕМИКС Эл Эл Си |
Связывающие комплемент аптамеры и средства против с5, пригодные для лечения глазных нарушений
|
WO2007115168A2
(en)
|
2006-03-31 |
2007-10-11 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of eg5 gene
|
EP2010226B1
(de)
|
2006-04-07 |
2014-01-15 |
The Research Foundation of State University of New York |
Transcobalaminrezeptor-Polypeptide, -Nukleinsäuren und -Modulatoren sowie entsprechende Verfahren zur Verwendung für die Modulation von Zellwachstum und die Behandlung von Krebs und Cobalaminmangel
|
EP2016060A4
(de)
*
|
2006-05-05 |
2010-08-04 |
Wallac Oy |
Auf azacycloalkanen basierende reagentien zum markieren von biomolekülen und davon abgeleitete konjugate
|
US20070275923A1
(en)
*
|
2006-05-25 |
2007-11-29 |
Nastech Pharmaceutical Company Inc. |
CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
CN101511181B
(zh)
|
2006-07-11 |
2013-08-21 |
新泽西医科和牙科大学 |
蛋白、编码该蛋白的核酸和相关的应用方法
|
US9505821B2
(en)
|
2006-10-03 |
2016-11-29 |
Rutgers, The State University Of New Jersey |
ATAP peptides, nucleic acids encoding the same and associated methods of use
|
US20100166743A1
(en)
|
2006-10-06 |
2010-07-01 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
EP2061901A2
(de)
|
2006-10-31 |
2009-05-27 |
Noxxon Pharma AG |
Verfahren zum nachweis eines einzel- oder doppelsträngigen nukleinsäuremoleküls
|
WO2008094370A2
(en)
|
2006-12-22 |
2008-08-07 |
University Of Utah Research Foundation |
Method of detecting ocular diseases and pathologic conditions and treatment of same
|
EP2146691A2
(de)
*
|
2007-04-17 |
2010-01-27 |
Baxter International Inc. |
Nukleinsäure-mikroteilchen zur abgabe in den lungen
|
JP5475643B2
(ja)
|
2007-05-04 |
2014-04-16 |
マリーナ バイオテック,インコーポレイテッド |
アミノ酸脂質およびその使用
|
WO2008147526A1
(en)
|
2007-05-23 |
2008-12-04 |
The Trustees Of The University Of Pennsylvania |
Targeted carriers for intracellular drug delivery
|
WO2009033027A2
(en)
|
2007-09-05 |
2009-03-12 |
Medtronic, Inc. |
Suppression of scn9a gene expression and/or function for the treatment of pain
|
US20090094716A1
(en)
*
|
2007-09-24 |
2009-04-09 |
Performance Plants, Inc. |
Plants having increased biomass
|
JP2011505144A
(ja)
|
2007-11-30 |
2011-02-24 |
ベイラー カレッジ オブ メディシン |
樹状細胞ワクチン組成物およびその使用
|
CA2708153C
(en)
|
2007-12-04 |
2017-09-26 |
Alnylam Pharmaceuticals, Inc. |
Carbohydrate conjugates as delivery agents for oligonucleotides
|
EP3100718B1
(de)
|
2008-01-02 |
2019-11-27 |
Arbutus Biopharma Corporation |
Verbesserte zusammensetzungen und verfahren zur freisetzung von nukleinsäuren
|
BRPI0911332A2
(pt)
|
2008-04-04 |
2019-09-24 |
Calando Pharmaceuticals Inc |
composições e uso de inibidores de epas1
|
PL2279254T3
(pl)
|
2008-04-15 |
2017-11-30 |
Protiva Biotherapeutics Inc. |
Nowe preparaty lipidowe do dostarczania kwasów nukleinowych
|
WO2009137095A2
(en)
|
2008-05-08 |
2009-11-12 |
The Johns Hopkins University |
Compositions and methods for modulating an immune response
|
US20110212021A1
(en)
|
2008-05-30 |
2011-09-01 |
Slack Frank J |
Targeted oligonucleotide compositions for modifying gene expression
|
AU2009274512A1
(en)
|
2008-07-25 |
2010-01-28 |
The Regents Of The University Of Colorado |
Clip inhibitors and methods of modulating immune function
|
AU2009290102A1
(en)
*
|
2008-09-05 |
2010-03-11 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
RNA monomers containing O-acetal levulinyl ester groups and their use in RNA microarrays
|
EP2341924A4
(de)
|
2008-10-02 |
2013-01-23 |
David Gladstone Inst |
Verfahren zur behandlung von hepatitis-c-virusinfektionen
|
US9139554B2
(en)
|
2008-10-09 |
2015-09-22 |
Tekmira Pharmaceuticals Corporation |
Amino lipids and methods for the delivery of nucleic acids
|
CN104382853A
(zh)
|
2008-10-16 |
2015-03-04 |
玛瑞纳生物技术有限公司 |
基因沉默治疗剂的脂质体有效递送方法和组合物
|
WO2010051105A1
(en)
|
2008-10-29 |
2010-05-06 |
China Synthetic Rubber Corporation |
Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
|
EP4241767A3
(de)
|
2008-11-10 |
2023-11-01 |
Arbutus Biopharma Corporation |
Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
|
EP3243504A1
(de)
|
2009-01-29 |
2017-11-15 |
Arbutus Biopharma Corporation |
Verbesserte lipidformulierung
|
US20100215660A1
(en)
|
2009-02-23 |
2010-08-26 |
Sarwar Hashmi |
Kruppel-like factors and fat regulation
|
JP6010458B2
(ja)
|
2009-04-03 |
2016-10-19 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. |
非対称二本鎖rnaによる特異的阻害のための、方法および組成物
|
EP2756845B1
(de)
|
2009-04-03 |
2017-03-15 |
Dicerna Pharmaceuticals, Inc. |
Verfahren und Zusammensetzungen für spezifische KRAS-Hemmung mit asymmetrischer Doppelstrang-RNA
|
US20120149756A1
(en)
|
2009-04-10 |
2012-06-14 |
Associatin Institut de Myologie |
Tricyclo-dna antisense oligonucleotides, compositions, and methods for the treatment of disease
|
US9724404B2
(en)
|
2009-04-13 |
2017-08-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
HPV particles and uses thereof
|
NZ621981A
(en)
|
2009-05-05 |
2015-09-25 |
Tekmira Pharmaceuticals Corp |
Lipid compositions
|
CA3045126A1
(en)
|
2009-05-05 |
2010-11-11 |
Arbutus Biopharma Corporation |
Methods of delivering oligonucleotides to immune cells
|
EP2430168B1
(de)
|
2009-05-16 |
2016-12-21 |
Kunyuan Cui |
Zusammensetzung mit kationischen amphiphilen und colipiden zur abgabe von heilmittelmolekülen
|
HUE056773T2
(hu)
|
2009-06-10 |
2022-03-28 |
Arbutus Biopharma Corp |
Továbbfejlesztett lipid készítmény
|
EP2449114B9
(de)
|
2009-07-01 |
2017-04-19 |
Protiva Biotherapeutics Inc. |
Neue lipidformulierungen zur abgabe von therapiemitteln in feste tumore
|
WO2011039646A2
(en)
|
2009-09-30 |
2011-04-07 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Papilloma virus -like particles for targeted gene delivery
|
US8450090B2
(en)
|
2009-10-06 |
2013-05-28 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for promoting fatty acid production in plants
|
US20120270930A1
(en)
|
2009-10-29 |
2012-10-25 |
Academisch Ziekenhuis Leiden H.O.D.N. Lumc |
Methods and compositions for dysferlin exon-skipping
|
WO2011062962A2
(en)
|
2009-11-17 |
2011-05-26 |
The Trustees Of The University Of Pennsylvania |
Smndelta7 degron: novel compositions and methods of use
|
CA2783372C
(en)
|
2009-12-07 |
2019-07-16 |
Muthiah Manoharan |
Compositions for nucleic acid delivery
|
ES2749426T3
(es)
|
2009-12-18 |
2020-03-20 |
Univ British Columbia |
Métodos y composiciones para administración de ácidos nucleicos
|
CN102770767A
(zh)
|
2010-02-10 |
2012-11-07 |
诺瓦提斯公司 |
用于肌肉生长的方法和组合物
|
ES2647390T3
(es)
|
2010-02-11 |
2017-12-21 |
Nanostring Technologies, Inc |
Composiciones y métodos para la detección preferencial de ARN pequeños mediante hibridación con puente y ligación
|
US9080171B2
(en)
|
2010-03-24 |
2015-07-14 |
RXi Parmaceuticals Corporation |
Reduced size self-delivering RNAi compounds
|
WO2011119842A1
(en)
|
2010-03-25 |
2011-09-29 |
The J. David Gladstone Institutes |
Compositions and methods for treating neurological disorders
|
WO2011120023A1
(en)
|
2010-03-26 |
2011-09-29 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting survivin gene expression uses thereof
|
WO2011133584A2
(en)
|
2010-04-19 |
2011-10-27 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting hras gene expression and uses thereof
|
US9816108B2
(en)
|
2010-04-23 |
2017-11-14 |
University Of Florida Research Foundation, Inc. |
rAAV-guanylate cyclase compositions and methods for treating lebers congenital amaurosis-1 (LCA1)
|
US20130190383A1
(en)
|
2010-04-26 |
2013-07-25 |
Marina Biotech, Inc. |
Nucleic acid compounds with conformationally restricted monomers and uses thereof
|
WO2011139842A2
(en)
|
2010-04-28 |
2011-11-10 |
Marina Biotech, Inc. |
Nucleic acid compounds for inhibiting fgfr3 gene expression and uses thereof
|
WO2012006243A2
(en)
|
2010-07-06 |
2012-01-12 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
|
WO2012006506A1
(en)
|
2010-07-09 |
2012-01-12 |
Massachusetts Institute Of Technology |
Metabolic gene, enzyme, and flux targets for cancer therapy
|
US20130202652A1
(en)
|
2010-07-30 |
2013-08-08 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for delivery of active agents
|
US20130323269A1
(en)
|
2010-07-30 |
2013-12-05 |
Muthiah Manoharan |
Methods and compositions for delivery of active agents
|
WO2012027206A1
(en)
|
2010-08-24 |
2012-03-01 |
Merck Sharp & Dohme Corp. |
SINGLE-STRANDED RNAi AGENTS CONTAINING AN INTERNAL, NON-NUCLEIC ACID SPACER
|
SG188666A1
(en)
|
2010-09-30 |
2013-05-31 |
Agency Science Tech & Res |
Methods and reagents for detection and treatment of esophageal metaplasia
|
US9260471B2
(en)
|
2010-10-29 |
2016-02-16 |
Sirna Therapeutics, Inc. |
RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA)
|
US9072766B2
(en)
|
2010-11-18 |
2015-07-07 |
Beth Israel Deaconess Medical Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT)
|
WO2012099755A1
(en)
|
2011-01-11 |
2012-07-26 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
CA2824235A1
(en)
|
2011-01-11 |
2012-07-19 |
Fate Therapeutics, Inc. |
Novel wnt compositions and therapeutic uses of such compositions
|
SG11201401314PA
(en)
|
2011-09-07 |
2014-09-26 |
Marina Biotech Inc |
Synthesis and uses of nucleic acid compounds with conformationally restricted monomers
|
WO2013049328A1
(en)
|
2011-09-27 |
2013-04-04 |
Alnylam Pharmaceuticals, Inc. |
Di-aliphatic substituted pegylated lipids
|
WO2013055789A1
(en)
|
2011-10-14 |
2013-04-18 |
Accugenomics, Inc. |
Nucleic acid amplification and use thereof
|
KR102102862B1
(ko)
|
2011-10-14 |
2020-04-22 |
제넨테크, 인크. |
항-HtrA1 항체 및 사용 방법
|
DK2790736T3
(en)
|
2011-12-12 |
2018-05-07 |
Oncoimmunin Inc |
In vivo delivery of oligonucleotides
|
US9562072B2
(en)
|
2011-12-27 |
2017-02-07 |
The J. David Gladstone Institutes |
Compositions and methods for regulating glucose metabolism
|
US9700639B2
(en)
|
2012-02-07 |
2017-07-11 |
Aura Biosciences, Inc. |
Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
|
BR112014020824B1
(pt)
|
2012-02-24 |
2022-10-04 |
Protiva Biotherapeutics Inc |
Lipídeo, partícula de lipídeo e composição farmacêutica
|
CA2874972C
(en)
|
2012-05-25 |
2023-06-20 |
Accugenomics, Inc. |
Nucleic acid amplification and use thereof
|
US11142762B2
(en)
|
2012-07-05 |
2021-10-12 |
The Trustees Of The University Of Pennsylvania |
U1 snRNP regulates gene expression and modulates oncogenicity
|
KR101520383B1
(ko)
|
2012-08-02 |
2015-05-15 |
에이비온 주식회사 |
Hpv 감염과 관련된 암의 치료용 조성물
|
WO2014039513A2
(en)
|
2012-09-04 |
2014-03-13 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive t cell transfer
|
ES2912033T3
(es)
|
2012-10-23 |
2022-05-24 |
Caris Science Inc |
Aptámeros y usos de los mismos
|
US10942184B2
(en)
|
2012-10-23 |
2021-03-09 |
Caris Science, Inc. |
Aptamers and uses thereof
|
US9939443B2
(en)
|
2012-12-19 |
2018-04-10 |
Caris Life Sciences Switzerland Holdings Gmbh |
Compositions and methods for aptamer screening
|
KR102092435B1
(ko)
|
2013-03-08 |
2020-03-24 |
예일 유니버시티 |
피부색소침착 감소용 조성물 및 방법
|
CN107056838A
(zh)
|
2013-03-15 |
2017-08-18 |
加利福尼亚大学董事会 |
无环核苷膦酸二酯
|
JP2016528887A
(ja)
|
2013-07-03 |
2016-09-23 |
ダイセルナ ファーマシューティカルズ, インコーポレイテッドDicerna Pharmaceuticals, Inc. |
二本鎖RNAによるα−1アンチトリプシンの特異的阻害のための方法及び組成物
|
JP6702862B2
(ja)
|
2013-07-11 |
2020-06-03 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
オリゴヌクレオチド−リガンドコンジュゲートおよびそれらの調製方法
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
JP2016533752A
(ja)
|
2013-08-28 |
2016-11-04 |
カリス ライフ サイエンシズ スウィッツァーランド ホー |
オリゴヌクレオチドプローブおよびその使用
|
JP6444417B2
(ja)
|
2013-09-18 |
2018-12-26 |
オーラ バイオサイエンシーズ, インコーポレイテッド |
腫瘍を診断および処置するためのウイルス様粒子結合体
|
EP3049085B9
(de)
|
2013-09-26 |
2021-08-18 |
Beth Israel Deaconess Medical Center, Inc. |
Sgk1 inhibitoren bei der behandlung von long-qt-syndrom
|
US9365610B2
(en)
|
2013-11-18 |
2016-06-14 |
Arcturus Therapeutics, Inc. |
Asymmetric ionizable cationic lipid for RNA delivery
|
WO2015074085A1
(en)
|
2013-11-18 |
2015-05-21 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for rna delivery
|
WO2015074010A2
(en)
|
2013-11-18 |
2015-05-21 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for cardiac regeneration
|
AR093574A1
(es)
|
2013-11-21 |
2015-06-10 |
Consejo Nac De Investig Cientificas Y Tecn (Conicet) |
Aptameros contra la proteina basica de mielina como agentes neuroprotectores
|
US10934550B2
(en)
|
2013-12-02 |
2021-03-02 |
Phio Pharmaceuticals Corp. |
Immunotherapy of cancer
|
JP7017309B2
(ja)
|
2013-12-20 |
2022-02-08 |
アセチロン ファーマシューティカルズ インコーポレイテッド |
多発性骨髄腫におけるヒストン脱アセチル化酵素6(hdac6)バイオマーカー
|
US9701966B2
(en)
|
2013-12-27 |
2017-07-11 |
Dicerna Pharmaceuticals, Inc. |
Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA
|
US9458464B2
(en)
|
2014-06-23 |
2016-10-04 |
The Johns Hopkins University |
Treatment of neuropathic pain
|
ES2903029T3
(es)
|
2014-07-03 |
2022-03-30 |
Univ Yale |
La inhibición de DICKKOPF2 (DKK2) suprime la formación de tumores
|
WO2016022363A2
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
HRP20220651T1
(hr)
|
2014-09-15 |
2022-08-19 |
The Regents Of The University Of California |
Nukleotidni analozi
|
CA2964168A1
(en)
|
2014-10-10 |
2016-04-14 |
Dicerna Pharmaceuticals, Inc. |
Therapeutic inhibition of lactate dehydrogenase and agents therefor
|
EP3206751A4
(de)
|
2014-10-14 |
2018-06-13 |
The J. David Gladstone Institutes |
Zusammensetzungen und verfahren zur reaktivierung von latentem immundefizienzvirus
|
WO2016081029A1
(en)
|
2014-11-18 |
2016-05-26 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for rna delivery
|
US20170355755A1
(en)
|
2014-11-21 |
2017-12-14 |
Yale University |
Compositions and methods for modulating salm5 and hvem
|
DK3569711T3
(da)
|
2014-12-15 |
2021-02-22 |
Dicerna Pharmaceuticals Inc |
Ligandmodificerede dobbeltstrengede nukleinsyrer
|
JP2017538427A
(ja)
|
2014-12-18 |
2017-12-28 |
インテグレイテッド ディーエヌエイ テクノロジーズ インコーポレイテッド |
Crispr系組成物及び使用方法
|
MA41629A
(fr)
|
2015-03-04 |
2018-01-09 |
Center For Human Reproduction |
Compositions et méthodes d'utilisation de l'hormone anti-müllérienne pour le traitement de l'infertilité
|
WO2016145128A1
(en)
|
2015-03-09 |
2016-09-15 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
CA2991045A1
(en)
|
2015-06-29 |
2017-01-05 |
Caris Science, Inc. |
Therapeutic oligonucleotides binding c1q
|
WO2017019918A1
(en)
|
2015-07-28 |
2017-02-02 |
Caris Science, Inc. |
Targeted oligonucleotides
|
US11273167B2
(en)
|
2015-08-03 |
2022-03-15 |
The Regents Of The University Of California |
Compositions and methods for modulating ABHD2 activity
|
KR20180095511A
(ko)
|
2015-10-30 |
2018-08-27 |
더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 |
표적화된 암 요법
|
IL295097A
(en)
|
2015-10-30 |
2022-09-01 |
Genentech Inc |
Anti-htra1 antibodies and methods of using them
|
CN109715802A
(zh)
|
2016-03-18 |
2019-05-03 |
卡里斯科学公司 |
寡核苷酸探针及其用途
|
MA45471A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de phosphatidylinositol-3-kinase et leurs utilisations
|
MA45349A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques egfr et leurs utilisations
|
MA45468A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques myc et utilisations
|
MA45470A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques kras et leurs utilisations
|
MA45328A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
MA45469A
(fr)
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Acides nucléiques de bêta-caténine et leurs utilisations
|
EP3448369A4
(de)
|
2016-04-29 |
2020-01-01 |
The Regents of The University of Colorado, A Body Corporate |
Verbindungen und zusammensetzungen zur behandlung des stoffwechselsyndroms und verfahren damit
|
WO2017205686A1
(en)
|
2016-05-25 |
2017-11-30 |
Caris Science, Inc. |
Oligonucleotide probes and uses thereof
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
EP3500696A4
(de)
|
2016-08-16 |
2020-04-08 |
Bluebird Bio, Inc. |
Il-10-rezeptor-alpha-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
|
EP3504335A4
(de)
|
2016-08-23 |
2020-04-15 |
Bluebird Bio, Inc. |
Tim3-homing-endonuklease-varianten, zusammensetzungen und verfahren zur verwendung
|
KR102451510B1
(ko)
|
2016-09-08 |
2022-10-07 |
2세븐티 바이오, 인코포레이티드 |
Pd-1 호밍 엔도뉴클레아제 변이체, 조성물 및 사용 방법
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
JP2019533996A
(ja)
|
2016-10-07 |
2019-11-28 |
インテグレイテツド・デイー・エヌ・エイ・テクノロジーズ・インコーポレイテツド |
S.ピオゲネスcas9変異遺伝子及びこれによってコードされるポリペプチド
|
DK3541833T3
(da)
|
2016-11-17 |
2024-04-02 |
2Seventy Bio Inc |
TGFß signalkonverter
|
WO2018098383A1
(en)
|
2016-11-22 |
2018-05-31 |
Integrated Dna Technologies, Inc. |
Crispr/cpf1 systems and methods
|
WO2018111947A1
(en)
|
2016-12-12 |
2018-06-21 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
US10526284B2
(en)
|
2016-12-21 |
2020-01-07 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
US10383952B2
(en)
|
2016-12-21 |
2019-08-20 |
Arcturus Therapeutics, Inc. |
Ionizable cationic lipid for RNA delivery
|
WO2018119163A1
(en)
|
2016-12-21 |
2018-06-28 |
Payne Joseph E |
Ionizable cationic lipid for rna delivery
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
CA3049424A1
(en)
|
2017-01-06 |
2018-07-12 |
Avidity Biosciences Llc |
Nucleic acid-polypeptide compositions and methods of inducing exon skipping
|
EP3583203B1
(de)
|
2017-02-15 |
2023-11-01 |
2seventy bio, Inc. |
Spenderreparaturtemplates für multiplex-genomeditierung
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
GB201711809D0
(en)
|
2017-07-21 |
2017-09-06 |
Governors Of The Univ Of Alberta |
Antisense oligonucleotide
|
EP3658573A1
(de)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Verfahren und zusammensetzungen zur entwicklung von basiseditoren unter verwendung von phagenunterstützter kontinuierlicher entwicklung (pace)
|
US11319532B2
(en)
|
2017-08-30 |
2022-05-03 |
President And Fellows Of Harvard College |
High efficiency base editors comprising Gam
|
US11306312B2
(en)
|
2017-09-01 |
2022-04-19 |
Thomas Jefferson University |
Compositions and methods for MYC messenger RNA inhibitors
|
CA3077213A1
(en)
|
2017-10-04 |
2019-04-11 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
EP3697906A1
(de)
|
2017-10-16 |
2020-08-26 |
The Broad Institute, Inc. |
Verwendungen von adenosinbasiseditoren
|
CN111902148A
(zh)
|
2017-12-06 |
2020-11-06 |
艾维迪提生物科学公司 |
治疗肌萎缩和强直性肌营养不良的组合物和方法
|
WO2019136459A1
(en)
|
2018-01-08 |
2019-07-11 |
Iovance Biotherapeutics, Inc. |
Processes for generating til products enriched for tumor antigen-specific t-cells
|
US11713446B2
(en)
|
2018-01-08 |
2023-08-01 |
Iovance Biotherapeutics, Inc. |
Processes for generating TIL products enriched for tumor antigen-specific T-cells
|
MX2020007046A
(es)
|
2018-01-08 |
2020-09-07 |
Iovance Biotherapeutics Inc |
Procesos para generar productos de linfocitos infiltrantes de tumores (til) enriquecidos para celulas t especificas de antigenos tumorales.
|
CN112424352A
(zh)
|
2018-05-11 |
2021-02-26 |
阿尔法阿诺麦里克公司 |
包括7′-5′-α-异头双环糖核苷的寡核苷酸缀合物
|
EP3891274B1
(de)
|
2018-12-06 |
2023-10-18 |
Arcturus Therapeutics, Inc. |
Zusammensetzungen und verfahren zur behandlung von ornithintranscarbamylase-mangel
|
DE112020001342T5
(de)
|
2019-03-19 |
2022-01-13 |
President and Fellows of Harvard College |
Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
|
US20220204975A1
(en)
|
2019-04-12 |
2022-06-30 |
President And Fellows Of Harvard College |
System for genome editing
|
AU2020289464A1
(en)
|
2019-06-06 |
2022-01-20 |
Avidity Biosciences, Inc. |
Nucleic acid-polypeptide compositions and uses thereof
|
PE20220968A1
(es)
|
2019-08-14 |
2022-06-10 |
Acuitas Therapeutics Inc |
Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
|
EP4121063A1
(de)
|
2020-03-19 |
2023-01-25 |
Avidity Biosciences, Inc. |
Zusammensetzungen und verfahren zur behandlung von fazioskapulohumeraler muskeldystrophie
|
CA3177180A1
(en)
|
2020-03-27 |
2021-09-30 |
Avidity Biosciences, Inc. |
Compositions and methods of treating muscle dystrophy
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート,インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
AU2021374966A1
(en)
|
2020-11-09 |
2023-06-15 |
1E Therapeutics, Ltd. |
Catalytic sequence based methods of treating or preventing bacterial infections
|
WO2022130388A2
(en)
|
2020-12-18 |
2022-06-23 |
Yeda Research And Development Co. Ltd. |
Compositions for use in the treatment of chd2 haploinsufficiency and methods of identifying same
|
WO2022144882A2
(en)
|
2020-12-28 |
2022-07-07 |
1E Therapeutics, Ltd. |
P21 mrna target areas for silencing
|
IL304068A
(en)
|
2020-12-28 |
2023-08-01 |
1E Therapeutics Ltd |
DNA enzymes against p21 messenger RNA
|
EP4288140A1
(de)
|
2021-02-05 |
2023-12-13 |
Iovance Biotherapeutics, Inc. |
Adjuvante therapie für krebs
|
EP4314016A1
(de)
|
2021-03-31 |
2024-02-07 |
Entrada Therapeutics, Inc. |
Zyklische zellen penetrierende peptide
|
EP4334437A1
(de)
|
2021-05-03 |
2024-03-13 |
Astellas Institute for Regenerative Medicine |
Verfahren zur erzeugung reifer hornhautendothelzellen
|
EP4337263A1
(de)
|
2021-05-10 |
2024-03-20 |
Entrada Therapeutics, Inc. |
Zusammensetzungen und verfahren zur modulation der interferon-regulatorischen faktor-5 (irf-5)-aktivität
|
KR20240012425A
(ko)
|
2021-05-10 |
2024-01-29 |
엔트라다 테라퓨틱스, 인크. |
세포내 치료제를 위한 조성물 및 방법
|
CA3217463A1
(en)
|
2021-05-10 |
2022-11-17 |
Ziqing QIAN |
Compositions and methods for modulating mrna splicing
|
EP4355875A1
(de)
|
2021-06-14 |
2024-04-24 |
2seventy bio, Inc. |
Verfahren zur aufreinigung einzelsträngiger rna
|
WO2022271955A1
(en)
|
2021-06-23 |
2022-12-29 |
Musc Foundation For Research Development |
Novel targeted shrna nanoparticles for cancer therapy
|
WO2022271818A1
(en)
|
2021-06-23 |
2022-12-29 |
Entrada Therapeutics, Inc. |
Antisense compounds and methods for targeting cug repeats
|
US20230138928A1
(en)
|
2021-08-05 |
2023-05-04 |
Sanegene Bio Usa Inc. |
1'-alkyl modified ribose derivatives and methods of use
|
CA3231330A1
(en)
|
2021-09-16 |
2023-03-23 |
Avidity Biosciences, Inc. |
Compositions and methods of treating facioscapulohumeral muscular dystrophy
|
CA3233113A1
(en)
|
2021-09-22 |
2023-03-30 |
Sanegene Bio Usa Inc. |
2'-alkyl or 3'-alkyl modified ribose derivatives for use in the in-vivo delivery of oligonucleotides
|
AU2022361238A1
(en)
|
2021-10-05 |
2024-04-11 |
Sanegene Bio Usa Inc. |
Polyhydroxylated cyclopentane derivatives and methods of use
|
WO2023144798A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Ionizable cationic lipids for lipid nanoparticles
|
WO2023144792A1
(en)
|
2022-01-31 |
2023-08-03 |
Genevant Sciences Gmbh |
Poly(alkyloxazoline)-lipid conjugates and lipid particles containing same
|
US20230346819A1
(en)
|
2022-02-22 |
2023-11-02 |
Sanegene Bio Usa Inc. |
5'-modified carbocyclic ribonucleotide derivatives and methods of use
|
WO2024015796A1
(en)
|
2022-07-11 |
2024-01-18 |
Sanegene Bio Usa Inc. |
Optimized 2'- modified ribose derivatives and methods of use
|
WO2024026474A1
(en)
|
2022-07-29 |
2024-02-01 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|